Archive for the ‘Cystic Fibrosis’ Category
Tuesday, August 26th, 2008
Kamada (TASE: KMDA), a bio-pharmaceutical company engaged in the development, manufacturing and marketing of specialty life-saving therapeutics, announced that it has completed a Phase II Study with Aerosolized Alpha-1 Antitrypsin (AAT), delivered via an optimized eFlow platform nebulizer (PARI Pharma GmbH), in cystic fibrosis (CF).
Posted in Cystic Fibrosis, medical-news | No Comments »
Friday, August 22nd, 2008
Researchers in Israel have found that a new drug for cystic fibrosis, PTC124, is able to bypass the genetic defect in the protein-making machinery of patients and improve the functioning of weakened cell membranes. The results in published in an upcoming edition of The Lancet.
Posted in Cystic Fibrosis, medical-news | No Comments »
Thursday, August 21st, 2008
New phase 2 data published today in The Lancet show that the investigational oral drug PTC124 demonstrates activity in nonsense-mutation cystic fibrosis (CF). The data show that treatment with PTC124 results in statistically significant improvements in the chloride channel function of patients with nonsense-mutation CF.
Posted in Cystic Fibrosis, medical-news | No Comments »
Thursday, July 31st, 2008
Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH) announced modifications to the clinical protocol for TIGER-2, the Company's ongoing second Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF). "The availability of the extensive data set from the positive TIGER-1 trial provides an excellent opportunity to optimize the TIGER-2 trial design," stated Christy L.
Posted in Cystic Fibrosis, medical-news | No Comments »
Wednesday, July 30th, 2008
Researchers in Japan and Canada have discovered a key component of the quality control mechanism that operates inside human cells - sometimes too well. The breakthrough has significant implications for the development of new treatments for cystic fibrosis (CF) and some other hereditary diseases, the researchers say. Their results were published July 25 in the journal Science. Dr.
Posted in Cystic Fibrosis, medical-news | No Comments »
Wednesday, July 30th, 2008
A London, Canada scientist studying cystic fibrosis (CF) has successfully corrected the defect which causes the overproduction of intestinal mucous in mice. This discovery by Dr. Richard Rozmahel, a scientist with the Lawson Health Research Institute, affiliated with The University of Western Ontario, has clear implications to understanding and treating this facet of the disease in humans.
Posted in Cystic Fibrosis, medical-news | No Comments »